At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- INCB161734 (drug), Placebo (drug), Investigator's choice of chemotherapy (drug)
- How long the study runs
- Study runs about 35 months (dates as stated)
- About the drug or intervention
- INCB161734 — drug: Oral; tablet · Placebo — drug: Oral; tablet · Investigator's choice of chemotherapy — drug: The investigator will select the chemotherapy in accordance with the protocol-defined requirements.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 588
- Started
- 2026-04-09
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for solid tumors
- • Phase3 - 588 participants
- • The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with solid tumors
Where?
- • Dundee - Investigative Site GB008
- • Guildford - Investigative Site GB011
- • Headington - Investigative Site GB002
- • Leeds - Investigative Site GB001
- • +5 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
- How fit you need to be: ECOG 0 or better
Biomarkers mentioned
What the study is looking for
- ✓confirmed by testing a sample that has spread PDAC with a KRAS G12D mutation
- ✓No prior systemic treatment in the that has spread setting
- ✓ECOG Performance status 0-1
- ✓healthy organ
Who cannot take part
- ✗Prior treatment with any KRAS inhibitor
- ✗Chronic or current active infection requiring systemic treatment within 1 week prior to the first dose of the study treatment
- ✗Known active CNS metastases
- ✗Other protocol-defined Inclusion/Exclusion Criteria may apply.
See the full criteria
Where Is This Study? (9 UK sites)
Investigative Site GB008
Dundee DD1 9SY, United Kingdom
Investigative Site GB011
Guildford GU2 7XX, United Kingdom
Investigative Site GB002
Headington OX3 7LE, United Kingdom
Investigative Site GB001
Leeds LS9 7TF, United Kingdom
Investigative Site GB009
London EC1A 7BE, United Kingdom
Investigative Site GB004
London NW3 2QG, United Kingdom
Investigative Site GB003
Manchester M20 4BX, United Kingdom
Investigative Site GB010
Northwood HA6 2RN, United Kingdom
Investigative Site GB005
Norwich NR4 7UY, United Kingdom
How to Get in Touch
Incyte Corporation Call Center (US)
Sponsor contactCONTACT
Incyte Corporation Call Center (ex-US)
Sponsor contactCONTACT